Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Gene Therapy Stock Plunges On Unexpected Delay For Sickle Cell Drug
09:36am, Thursday, 05'th Nov 2020
Bluebird Bio announced a delay for a gene therapy in treating sickle cell disease, leading BLUE stock to tumble early Thursday. Now, the company expects to ask for approval in late 2022.
Were These Hedge Funds Wrong About Buying bluebird bio Inc (BLUE)?
09:08am, Tuesday, 03'rd Nov 2020
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in
7 Cutting-Edge Biotech Stocks for Tomorrow
08:59am, Wednesday, 28'th Oct 2020
Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.
bluebird bio to present new data from clinical studies of elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy at the 46th EBMT Annual Meeting.
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Companies Like bluebird bio (NASDAQ:BLUE) Are In A Position To Invest In Growth
11:22am, Wednesday, 12'th Aug 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
bluebird bio Appoints Denice Torres to Board of Directors
11:01am, Tuesday, 11'th Aug 2020
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors.
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
12:00am, Tuesday, 11'th Aug 2020
The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
Why Bluebird Bio's Stock Is Trading Higher Today
03:42pm, Thursday, 06'th Aug 2020
Bluebird Bio (NASDAQ: BLUE) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year. Wedbush also maintained its Outperform rating on th
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
12:25am, Thursday, 06'th Aug 2020
Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
08:10pm, Wednesday, 05'th Aug 2020
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2020 and shared recent operational progress.
Why Earnings Season Could Be Great for bluebird bio (BLUE)
12:41pm, Wednesday, 05'th Aug 2020
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Global Hematopoietic Stem Cells Transplantation (HSCT) Market will grow by USD 4.64 bn during 2020-2024
bluebird bio Announces August Investor Event
12:00pm, Friday, 31'st Jul 2020
bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET.
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:33pm, Thursday, 30'th Jul 2020
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
